Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CHAKRA P CHAULAGAIN

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1487824124
CMS profile
1202560
Location
WESTON, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$38,138.07

73 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Page 2 of 2; records 51–73 of 73 matching records. This page contains 23 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CHAKRA P CHAULAGAIN

NPI 1487824124 · CMS profile ID 1202560

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

WESTON, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–73 of 73 matching records. This page contains 23 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1487824124?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CHAKRA P CHAULAGAIN, NPI 1487824124, CMS profile ID 1202560. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–73 of 73 matching records. This page contains 23 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1487824124?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). CHAKRA P CHAULAGAIN, NPI 1487824124, CMS profile ID 1202560. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–73 of 73 matching records. This page contains 23 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1487824124?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
CHAKRA P CHAULAGAIN, NPI 1487824124, CMS profile ID 1202560, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–73 of 73 matching records. This page contains 23 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1487824124?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

73 matching records · $38,138.07 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 73 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–73 of 73.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Takeda Pharmaceuticals U.S.A., Inc. $23.4406/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055367067 CMS
Incyte Corporation $19.5406/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044529315 CMS
Janssen Biotech, Inc. $114.3006/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988191723 CMS
Janssen Biotech, Inc. $4.3106/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988191753 CMS
PFIZER INC. $5.9206/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050364006 CMS
Celgene Corporation $16.3406/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014884053 CMS
Bayer Healthcare Pharmaceuticals Inc. $16.6506/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000505161 CMS
Celgene Corporation $19.5506/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014884043 CMS
BeiGene USA, Inc. $15.3705/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051189559 CMS
Janssen Biotech, Inc. $99.9905/10/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988191715 CMS
Janssen Biotech, Inc. $19.1905/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988191733 CMS
Incyte Corporation $26.0904/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044529091 CMS
Janssen Biotech, Inc. $19.6703/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988191743 CMS
Janssen Biotech, Inc. $11.3703/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988191765 CMS
Seagen Inc. $18.6203/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 995788061 CMS
Takeda Pharmaceuticals U.S.A., Inc. $20.7903/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055367065 CMS
PFIZER INC. $19.5003/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049248273 CMS
Apellis Pharmaceuticals, Inc. $17.6402/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056369269 CMS
Eisai Inc. $15.8002/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023304983 CMS
E.R. Squibb & Sons, L.L.C. $1,779.0002/02/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014883863 CMS
Incyte Corporation $26.5801/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044528951 CMS
PFIZER INC. $0.1401/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050305873 CMS
PFIZER INC. $18.9801/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050704105 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $13,187.94 17
PY2020 $10,394.97 9
PY2021 $21,252.35 27
PY2022 $44,596.21 68
PY2023 $38,138.07 73
PY2024 $25,695.01 98
PY2025 $44,223.38 107

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $941,664.20 69
PY2024 Principal investigator $492,010.28 44
PY2023 Principal investigator $488,703.26 57
PY2022 Principal investigator $207,108.60 20
PY2021 Principal investigator $120,138.00 23
PY2020 Principal investigator $101,964.00 23
PY2019 Principal investigator $47,018.00 9

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

69 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $660.00 12/29/2025 Non-covered Recipient Entity
CLEVELAND CLINIC FLORIDA
A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant No dispute reported 06/30/2026 1175398840
Principal investigator 1 Janssen Research & Development, LLC $12,691.64 12/26/2025 Non-covered Recipient Entity
CLEVELAND CLINIC FLORIDA
A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or not Intended for Autologous Stem Cell Transplant as Initial Therapy. No dispute reported 06/30/2026 1175398825
Principal investigator 1 Janssen Research & Development, LLC $5,572.00 12/25/2025 Non-covered Recipient Entity
CLEVELAND CLINIC FLORIDA
A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or not Intended for Autologous Stem Cell Transplant as Initial Therapy. No dispute reported 06/30/2026 1175398820
Principal investigator 1 Janssen Research & Development, LLC $67,326.00 12/25/2025 Non-covered Recipient Entity
CLEVELAND CLINIC FLORIDA
A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or not Intended for Autologous Stem Cell Transplant as Initial Therapy. No dispute reported 06/30/2026 1175399118
Principal investigator 1 Janssen Research & Development, LLC $5,139.00 12/15/2025 Non-covered Recipient Entity
CLEVELAND CLINIC FLORIDA
A Phase 1 Randomized, Open-Label Pharmacokinetic Comparability Study Comparing Pre- and Post-change Teclistamab in Participants with Relapsed/Refractory Multiple Myeloma No dispute reported 06/30/2026 1175399065
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $23,076.00 11/26/2025 Non-covered Recipient Entity
Cleveland Clinic Florida Aetna Aco
A study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1) No dispute reported 06/30/2026 1235998118
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $11,317.50 11/26/2025 Non-covered Recipient Entity
Cleveland Clinic Florida Aetna Aco
A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT) in Participants with Newly Diagnosed Multiple Myeloma (NDMM) (Excaliber-Maintenance) No dispute reported 06/30/2026 1235998120
Principal investigator 1 Janssen Research & Development, LLC $2,139.00 11/24/2025 Non-covered Recipient Entity
CLEVELAND CLINIC FLORIDA
A Phase 1 Randomized, Open-Label Pharmacokinetic Comparability Study Comparing Pre- and Post-change Teclistamab in Participants with Relapsed/Refractory Multiple Myeloma No dispute reported 06/30/2026 1175398854
Principal investigator 1 ABBVIE INC. $3,300.00 11/20/2025 Non-covered Recipient Entity
CLEVELAND CLINIC OF FLORIDA
A Study of Venetoclax and Dexamethasone Compared With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202524808
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $9,824.00 11/20/2025 Non-covered Recipient Entity
Cleveland Clinic Florida Aetna Aco
A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1235998122
Principal investigator 1 Janssen Research & Development, LLC $3,450.00 11/17/2025 Non-covered Recipient Entity
CLEVELAND CLINIC FLORIDA
A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Monoclonal Antibody and Lenalidomide No dispute reported 06/30/2026 1175399088
Principal investigator 1 Janssen Research & Development, LLC $5,962.00 11/10/2025 Non-covered Recipient Entity
CLEVELAND CLINIC FLORIDA
A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or not Intended for Autologous Stem Cell Transplant as Initial Therapy. No dispute reported 06/30/2026 1175399149
Principal investigator 1 Janssen Research & Development, LLC $475.00 11/06/2025 Non-covered Recipient Entity
CLEVELAND CLINIC FLORIDA
A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant No dispute reported 06/30/2026 1175398904
Principal investigator 1 Janssen Research & Development, LLC $25,770.63 11/03/2025 Non-covered Recipient Entity
CLEVELAND CLINIC FLORIDA
A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or not Intended for Autologous Stem Cell Transplant as Initial Therapy. No dispute reported 06/30/2026 1175398988
Principal investigator 1 Janssen Research & Development, LLC $23,848.00 10/31/2025 Non-covered Recipient Entity
CLEVELAND CLINIC FLORIDA
A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or not Intended for Autologous Stem Cell Transplant as Initial Therapy. No dispute reported 06/30/2026 1175398847
Principal investigator 1 Janssen Research & Development, LLC $1,670.00 10/24/2025 Non-covered Recipient Entity
CLEVELAND CLINIC FLORIDA
A Phase 1 Randomized, Open-Label Pharmacokinetic Comparability Study Comparing Pre- and Post-change Teclistamab in Participants with Relapsed/Refractory Multiple Myeloma No dispute reported 06/30/2026 1175398911
Principal investigator 1 Janssen Research & Development, LLC $2,050.00 10/20/2025 Non-covered Recipient Entity
CLEVELAND CLINIC FLORIDA
A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or not Intended for Autologous Stem Cell Transplant as Initial Therapy. No dispute reported 06/30/2026 1175399072
Principal investigator 1 Janssen Research & Development, LLC $4,205.00 10/20/2025 Non-covered Recipient Entity
CLEVELAND CLINIC FLORIDA
A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or not Intended for Autologous Stem Cell Transplant as Initial Therapy. No dispute reported 06/30/2026 1175399102
Principal investigator 1 Janssen Research & Development, LLC $27,746.60 10/20/2025 Non-covered Recipient Entity
CLEVELAND CLINIC FLORIDA
A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or not Intended for Autologous Stem Cell Transplant as Initial Therapy. No dispute reported 06/30/2026 1175399125
Principal investigator 1 Celgene Corporation $32,771.00 10/08/2025 Non-covered Recipient Entity
Cleveland Clinic Florida Weston
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP Chemotherapy in Participants with Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1) No dispute reported 06/30/2026 1222304503
Principal investigator 1 Janssen Research & Development, LLC $1,550.00 10/03/2025 Non-covered Recipient Entity
CLEVELAND CLINIC FLORIDA
A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Monoclonal Antibody and Lenalidomide No dispute reported 06/30/2026 1175398900
Principal investigator 1 Janssen Research & Development, LLC $3,100.00 10/03/2025 Non-covered Recipient Entity
CLEVELAND CLINIC FLORIDA
A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Monoclonal Antibody and Lenalidomide No dispute reported 06/30/2026 1175399023
Principal investigator 1 Janssen Research & Development, LLC $26,087.41 10/02/2025 Non-covered Recipient Entity
CLEVELAND CLINIC FLORIDA
A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or not Intended for Autologous Stem Cell Transplant as Initial Therapy. No dispute reported 06/30/2026 1175398981
Principal investigator 1 Janssen Research & Development, LLC $2,000.00 09/29/2025 Non-covered Recipient Entity
CLEVELAND CLINIC FLORIDA
A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Ther No dispute reported 06/30/2026 1175399042
Principal investigator 1 Janssen Research & Development, LLC $2,906.00 09/22/2025 Non-covered Recipient Entity
CLEVELAND CLINIC FLORIDA
A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or No dispute reported 06/30/2026 1175398888
Principal investigator 1 Janssen Research & Development, LLC $1,550.00 09/19/2025 Non-covered Recipient Entity
CLEVELAND CLINIC FLORIDA
A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Ther No dispute reported 06/30/2026 1175398940
Principal investigator 1 Janssen Research & Development, LLC $1,550.00 09/19/2025 Non-covered Recipient Entity
CLEVELAND CLINIC FLORIDA
A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Ther No dispute reported 06/30/2026 1175398964
Principal investigator 1 Janssen Research & Development, LLC $650.00 09/19/2025 Non-covered Recipient Entity
CLEVELAND CLINIC FLORIDA
A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Ther No dispute reported 06/30/2026 1175399047
Principal investigator 1 Janssen Research & Development, LLC $1,290.00 09/19/2025 Non-covered Recipient Entity
CLEVELAND CLINIC FLORIDA
A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Ther No dispute reported 06/30/2026 1175399114
Principal investigator 1 Janssen Research & Development, LLC $370.00 09/04/2025 Non-covered Recipient Entity
CLEVELAND CLINIC FLORIDA
A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant No dispute reported 06/30/2026 1175398928
Principal investigator 1 Janssen Research & Development, LLC $2,025.00 09/01/2025 Non-covered Recipient Entity
CLEVELAND CLINIC FLORIDA
A Phase 1 Randomized, Open-Label Pharmacokinetic Comparability Study Comparing Pre- and Post-change Teclistamab in Participants with Relapsed/Refractory Multiple Myeloma No dispute reported 06/30/2026 1175399083
Principal investigator 1 Janssen Research & Development, LLC $1,670.00 08/25/2025 Non-covered Recipient Entity
CLEVELAND CLINIC FLORIDA
A Phase 1 Randomized, Open-Label Pharmacokinetic Comparability Study Comparing Pre- and Post-change Teclistamab in Participants with Relapsed/Refractory Multiple Myeloma No dispute reported 06/30/2026 1175398970
Principal investigator 1 Janssen Research & Development, LLC $5,360.00 08/21/2025 Non-covered Recipient Entity
CLEVELAND CLINIC FLORIDA
A Phase 1 Randomized, Open-Label Pharmacokinetic Comparability Study Comparing Pre- and Post-change Teclistamab in Participants with Relapsed/Refractory Multiple Myeloma No dispute reported 06/30/2026 1175398830
Principal investigator 1 BeOne Medicines USA, Inc. $27,287.80 08/19/2025 Non-covered Recipient Entity
Cleveland Clinic Florida
A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma No dispute reported 06/30/2026 1190329119
Principal investigator 1 Janssen Research & Development, LLC $3,425.00 08/08/2025 Non-covered Recipient Entity
CLEVELAND CLINIC FLORIDA
A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant No dispute reported 06/30/2026 1175398917
Principal investigator 1 BeOne Medicines Ltd. $33,536.00 07/31/2025 Non-covered Recipient Entity
Cleveland Clinic Florida
A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma No dispute reported 06/30/2026 1190330465
Principal investigator 1 Janssen Research & Development, LLC $185.00 07/28/2025 Non-covered Recipient Entity
CLEVELAND CLINIC FLORIDA
A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant No dispute reported 06/30/2026 1175399145
Principal investigator 1 Janssen Research & Development, LLC $2,050.00 07/24/2025 Non-covered Recipient Entity
CLEVELAND CLINIC FLORIDA
A Phase 1 Randomized, Open-Label Pharmacokinetic Comparability Study Comparing Pre- and Post-change Teclistamab in Participants with Relapsed/Refractory Multiple Myeloma No dispute reported 06/30/2026 1175398958
Principal investigator 1 Janssen Research & Development, LLC $41,150.00 07/18/2025 Non-covered Recipient Entity
CLEVELAND CLINIC FLORIDA
A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or No dispute reported 06/30/2026 1175398883
Principal investigator 1 Janssen Research & Development, LLC $5,800.00 07/14/2025 Non-covered Recipient Entity
CLEVELAND CLINIC FLORIDA
A Phase 1 Randomized, Open-Label Pharmacokinetic Comparability Study Comparing Pre- and Post-change Teclistamab in Participants with Relapsed/Refractory Multiple Myeloma No dispute reported 06/30/2026 1175399092
Principal investigator 1 Janssen Research & Development, LLC $4,550.00 06/23/2025 Non-covered Recipient Entity
CLEVELAND CLINIC FLORIDA
A Phase 1 Randomized, Open-Label Pharmacokinetic Comparability Study Comparing Pre- and Post-change Teclistamab in Participants with Relapsed/Refractory Multiple Myeloma No dispute reported 06/30/2026 1175398863
Principal investigator 1 Celgene Corporation $26,700.00 06/04/2025 Non-covered Recipient Entity
Cleveland Clinic Florida Weston
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP Chemotherapy in Participants with Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1) No dispute reported 06/30/2026 1222304577
Principal investigator 1 Celgene Corporation $45,270.00 06/02/2025 Non-covered Recipient Entity
Cleveland Clinic Florida Weston
A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1222304493
Principal investigator 1 Janssen Research & Development, LLC $660.00 05/30/2025 Non-covered Recipient Entity
CLEVELAND CLINIC FLORIDA
A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant No dispute reported 06/30/2026 1175399130
Principal investigator 1 Janssen Research & Development, LLC $3,080.00 05/26/2025 Non-covered Recipient Entity
CLEVELAND CLINIC FLORIDA
A Phase 1 Randomized, Open-Label Pharmacokinetic Comparability Study Comparing Pre- and Post-change Teclistamab in Participants with Relapsed/Refractory Multiple Myeloma No dispute reported 06/30/2026 1175398878
Principal investigator 1 Janssen Research & Development, LLC $4,280.00 05/26/2025 Non-covered Recipient Entity
CLEVELAND CLINIC FLORIDA
A Phase 1 Randomized, Open-Label Pharmacokinetic Comparability Study Comparing Pre- and Post-change Teclistamab in Participants with Relapsed/Refractory Multiple Myeloma No dispute reported 06/30/2026 1175399053
Principal investigator 1 Janssen Research & Development, LLC $6,554.00 05/19/2025 Non-covered Recipient Entity
CLEVELAND CLINIC FLORIDA
A Phase 1 Randomized, Open-Label Pharmacokinetic Comparability Study Comparing Pre- and Post-change Teclistamab in Participants with Relapsed/Refractory Multiple Myeloma No dispute reported 06/30/2026 1175399000
Principal investigator 1 Janssen Research & Development, LLC $1,775.00 04/28/2025 Non-covered Recipient Entity
CLEVELAND CLINIC FLORIDA
A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant No dispute reported 06/30/2026 1175398893
Principal investigator 1 Alexion Pharmaceuticals, Inc. $76,736.70 04/23/2025 Non-covered Recipient Entity
CLEVELAND CLINIC WESTON
A Phase 3, Double Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL 101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia in Treatment Naive Patients with Stage IIIa AL Cardiac Amyloidosis. No dispute reported 06/30/2026 1185542286
Principal investigator 1 Janssen Research & Development, LLC $5,140.00 04/21/2025 Non-covered Recipient Entity
CLEVELAND CLINIC FLORIDA
A Phase 1 Randomized, Open-Label Pharmacokinetic Comparability Study Comparing Pre- and Post-change Teclistamab in Participants with Relapsed/Refractory Multiple Myeloma No dispute reported 06/30/2026 1175399028
Principal investigator 1 Alexion Pharmaceuticals, Inc. $40,062.60 04/02/2025 Non-covered Recipient Entity
CLEVELAND CLINIC WESTON
A Phase 3, Double Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL 101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment Naive Patients with Stage IIIb AL Cardiac Amyloidosis. No dispute reported 06/30/2026 1185542288
Principal investigator 1 Janssen Research & Development, LLC $370.00 03/31/2025 Non-covered Recipient Entity
CLEVELAND CLINIC FLORIDA
A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant No dispute reported 06/30/2026 1175398836
Principal investigator 1 Janssen Research & Development, LLC $13,466.00 03/24/2025 Non-covered Recipient Entity
CLEVELAND CLINIC FLORIDA
A Phase 1 Randomized, Open-Label Pharmacokinetic Comparability Study Comparing Pre- and Post-change Teclistamab in Participants with Relapsed/Refractory Multiple Myeloma No dispute reported 06/30/2026 1175398994
Principal investigator 1 Janssen Research & Development, LLC $1,035.00 03/20/2025 Non-covered Recipient Entity
CLEVELAND CLINIC FLORIDA
A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant No dispute reported 06/30/2026 1175398858
Principal investigator 1 Janssen Research & Development, LLC $25,525.90 03/17/2025 Non-covered Recipient Entity
CLEVELAND CLINIC FLORIDA
A Phase 1 Randomized, Open-Label Pharmacokinetic Comparability Study Comparing Pre- and Post-change Teclistamab in Participants with Relapsed/Refractory Multiple Myeloma No dispute reported 06/30/2026 1175399160
Principal investigator 1 Janssen Research & Development, LLC $26,829.00 03/10/2025 Non-covered Recipient Entity
CLEVELAND CLINIC FLORIDA
A Phase 1 Randomized, Open-Label Pharmacokinetic Comparability Study Comparing Pre- and Post-change Teclistamab in Participants with Relapsed/Refractory Multiple Myeloma No dispute reported 06/30/2026 1175398945
Principal investigator 1 Janssen Research & Development, LLC $475.00 03/06/2025 Non-covered Recipient Entity
CLEVELAND CLINIC FLORIDA
A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant No dispute reported 06/30/2026 1175399034
Principal investigator 1 Janssen Research & Development, LLC $4,280.00 03/03/2025 Non-covered Recipient Entity
CLEVELAND CLINIC FLORIDA
A Phase 1 Randomized, Open-Label Pharmacokinetic Comparability Study Comparing Pre- and Post-change Teclistamab in Participants with Relapsed/Refractory Multiple Myeloma No dispute reported 06/30/2026 1175398933
Principal investigator 1 Alexion Pharmaceuticals, Inc. $33,288.30 02/25/2025 Non-covered Recipient Entity
CLEVELAND CLINIC FLORIDA
A Phase 3, Double Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL 101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment Naive Patients with Stage IIIb AL Cardiac Amyloidosis. No dispute reported 06/30/2026 1185542290
Principal investigator 1 Janssen Research & Development, LLC $4,100.00 02/24/2025 Non-covered Recipient Entity
CLEVELAND CLINIC FLORIDA
A Phase 1 Randomized, Open-Label Pharmacokinetic Comparability Study Comparing Pre- and Post-change Teclistamab in Participants with Relapsed/Refractory Multiple Myeloma No dispute reported 06/30/2026 1175398868
Principal investigator 1 Janssen Research & Development, LLC $1,350.00 02/20/2025 Non-covered Recipient Entity
CLEVELAND CLINIC FLORIDA
A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Ther No dispute reported 06/30/2026 1175399059
Principal investigator 1 Alexion Pharmaceuticals, Inc. $2,981.34 02/18/2025 Non-covered Recipient Entity
CLEVELAND CLINIC WESTON
A Phase 3, Double Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL 101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia in Treatment Naive Patients with Stage IIIa AL Cardiac Amyloidosis. No dispute reported 06/30/2026 1185542284
Principal investigator 1 Alexion Pharmaceuticals, Inc. $1,992.06 02/18/2025 Non-covered Recipient Entity
CLEVELAND CLINIC WESTON
A Phase 3, Double Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL 101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment Naive Patients with Stage IIIb AL Cardiac Amyloidosis. No dispute reported 06/30/2026 1185542292
Principal investigator 1 Janssen Research & Development, LLC $1,241.00 02/10/2025 Non-covered Recipient Entity
CLEVELAND CLINIC FLORIDA
A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant No dispute reported 06/30/2026 1175399012
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $6,410.92 01/27/2025 Covered Recipient Teaching Hospital
Cleveland Clinic Hospital
A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT) in Participants with Newly Diagnosed Multiple Myeloma (NDMM) (Excaliber-Maintenance) No dispute reported 06/30/2026 1236001529
Principal investigator 1 Janssen Research & Development, LLC $2,200.00 01/27/2025 Non-covered Recipient Entity
CLEVELAND CLINIC FLORIDA
A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant No dispute reported 06/30/2026 1175398952
Principal investigator 1 Celgene Corporation $54,011.00 01/24/2025 Non-covered Recipient Entity
Cleveland Clinic Florida Weston
A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1222304535
Principal investigator 1 Alexion Pharmaceuticals, Inc. $34,098.30 01/08/2025 Non-covered Recipient Entity
CLEVELAND CLINIC FLORIDA
A Phase 3, Double Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL 101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia in Treatment Naive Patients with Stage IIIa AL Cardiac Amyloidosis. No dispute reported 06/30/2026 1185542282
Principal investigator 1 Celgene Corporation $80,666.50 01/08/2025 Non-covered Recipient Entity
Cleveland Clinic Florida Weston
A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT) in Participants with Newly Diagnosed Multiple Myeloma (NDMM) (Excaliber-Maintenance) No dispute reported 06/30/2026 1222304487